Skip to playerSkip to main contentSkip to footer
  • 1/24/2020
Biocon reported its Q3 numbers and it was a mixed set. Revenue was in-line, up around 13.5 percent, but margins took a hit due to higher R&D and remediation expense on the Malaysia facility.

Category

🗞
News

Recommended